Ovarian Cancer Trial, Recruiting NCT06061874 Sponsor: Jules Bordet Institute Condition: Ovarian Cancer
Back to Ovarian Cancer

Ovarian Cancer Trial, Recruiting

NCT06061874
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with colorectal (bowel) or ovarian cancer, confirmed by a tissue sample (biopsy).
  • Your cancer has spread, or is suspected to have spread, to the lining of the abdomen (the peritoneum).
  • You are scheduled for surgery aimed at completely removing the cancer spread in the abdomen, possibly with chemotherapy beforehand.
  • Your general health and ability to carry out daily activities meets a certain minimum level, as assessed by your doctor (confirm with trial site).
  • You are willing and able to sign a consent form before any study-related checks begin.

Who may not be able to join:

  • Your cancer has spread to areas outside the abdomen that cannot be surgically removed, or you have more than 3 spots of cancer on the liver.
  • You have a long-term inflammatory condition, especially affecting the gut, such as inflammatory bowel disease or Crohn's disease.
  • You are currently pregnant or breastfeeding.
  • You have been diagnosed with another cancer within the last 3 years, unless it was an early-stage cervical cancer or a certain type of skin cancer that has already been fully treated.
  • You have another serious health condition that, in your doctor's opinion, could affect your ability to complete the study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Patrick Flamen, Jules Bordet Institute

Phone: +32 (0) 2 541 37 81

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Jules Bordet Institute
Registry
ClinicalTrials.gov
Start date
30 May 2023
Est. completion
1 June 2025

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

Correlation of the Ga68-FAPI PET/CT derived PCI (peritoneal cancer index) score with the intraoperative PCI based on histopathology of resected specimen (the reference standard)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov